



Press Release

Turku, Finland
December 4, 2007

EC/EMA has granted an Orphan Drug Designation for Traumakine™

Following the European Medicines Agency (EMA) recommendation (EMA/OD/080/07), which was based on the earlier and positive decision by its Committee for Orphan Medicinal Products (COMP) (COMP/447815/2007), the European Commission has granted orphan drug designation to Faron's lead product Traumakine™ with the register number EU/3/07/505. This status was applied for Traumakine's first planned indication, namely the treatment of Acute Lung Injury (ALI). Traumakine's active pharmaceutical ingredient is interferon-beta (IFN-beta) and the Company together with its scientific network has demonstrated that this new use of IFN-beta prevents leakage of vascular beds, one of the first signs of severe lung injury, which leads to respiration dysfunction. This life threatening condition kills between 30-40 percent of the patients and currently there is no pharmacological treatment available for ALI.

- Traumakine has become the most fast progressing drug candidate within Faron pipeline (www.faronpharmaceuticals.com) and this orphan designation is a significant milestone of that program, comments Company's CEO **Markku Jalkanen**. We hope to get a similar approval from the FDA later this year, continues Jalkanen.
- Faron is currently seeking scientific advice from MHRA (the UK Medicines and Healthcare products Regulatory Agency) in order to submit a clinical trial application (CTA) early next year, says Faron's Advisor, Dr. Alan Boyd. If accepted, as we believe, we can enroll the first ALI patient during Q2-08 to a phase I/II study with primary focus in safety and initial efficacy, which will help us to design the subsequent pivotal phase II/III study, finishes Boyd.

Faron Pharmaceuticals, Ltd. is a virtual drug discovery and development company with three major drug development projects focusing on acute traumas, incipient vasculopathies, inflammatory diseases, and cancer metastasis.

Further information:

Markku Jalkanen, CEO
Phone: +358-40-520-6124
E-mail: markku.jalkanen@faronpharmaceuticals.com
www.faronpharmaceuticals.com

Faron Pharmaceuticals Ltd.

Tykistökatu 6 B, FIN-20520 Turku, Finland

Tel. +358 2 478 8401, Fax +358 2 478 8411, www.faronpharmaceuticals.com

Business ID 2068285-4, Domicile Turku